Allogene Therapeutics, Inc. Common Stock
$1.69
-$0.04 (-2.60%)
$1.67Day Range$1.74
Key Statistics
Market Cap
$597.70M
Shares Outstanding
345.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 11, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$1.73
Day High
$1.74
Day Low
$1.67
Volume
2.72M
VWAP
$1.69
Prev Close
$1.73
Transactions
--
Acc. Volume
--
About Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836152 employees210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080(650) 457-2700IPO Oct 11, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001737287
- Composite FIGI
- BBG00KHRRDX3
- Share Class FIGI
- BBG00KHRRDY2
- Ticker Root
- ALLO
- SIC Code
- 2836
About Allogene Therapeutics, Inc. Common Stock (ALLO) Stock
Allogene Therapeutics, Inc. Common Stock (ALLO) closed the 2026-09-18 session at $1.69, down 2.60% versus the previous close (-0.04). The stock opened at $1.73 and traded between $1.67 and $1.74 during that session. Session trading volume was 2.7M shares. The volume-weighted average price (VWAP) is $1.69.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Allogene Therapeutics, Inc. Common Stock has a market capitalization of $597.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ALLO is listed on the XNAS exchange. The company employs approximately 152 people. Allogene Therapeutics, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2018-10-11.
On this page you can find market ALLO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.